Perrigo Company plc
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Albert A. Manzone
- Full Time Employees
- 8,100
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- The Sharp Building Dublin DU Ireland D02 TY74
- IPO Date
- Dec 17, 1991
- CIK
- 0001585364
- Website
- perrigo.com
- Similar Companies
- Business
- Perrigo Company plc (NYSE: PRGO) manufactures and distributes a broad portfolio of over-the-counter (OTC) consumer self-care products and pharmaceutical solutions worldwide; its core offerings encompass upper respiratory products including cough suppressants, expectorants, sinus and allergy relief; infant formulas and nutritional beverages in the nutrition segment; digestive health products such as antacids, anti-diarrheals and anti-heartburn remedies; pain and sleep aids; as well as skin care, women's health and oral care items under store-brand private labels and select branded lines; the company additionally supplies active pharmaceutical ingredients and provides contract manufacturing services. Founded in 1887 and headquartered in Dublin, Ireland, Perrigo operates manufacturing facilities and distribution networks across North America, Europe including the UK and Ireland, and select international markets, serving retailers, healthcare providers and consumers seeking affordable health and wellness alternatives. In recent developments, Perrigo signed a binding agreement in 2024 to divest its HRA Pharma Rare Diseases business to ESTEVE for up to €275 million, enhancing focus on core self-care categories; announced the sale of its Dermacosmetics business to Kairos Bidco AB, managed by KKR, for up to €327 million in July 2025; launched new products in nutrition, skin care and women's health categories; initiated Project Energize targeting $140 million to $170 million in annualized pre-tax savings by end-2026; refinanced $1.1 billion in debt including redemption of 4.375% Senior Notes due 2026 and repayment of 3.9% Senior Notes due 2024; and began a strategic review of its infant formula business in November 2025 to optimize cash flows and reassess $240 million in planned investments.
Perrigo: The Rebound Is Just Getting Started
PRGO vs. NEOG: Which Stock Is the Better Value Option?
Are Investors Undervaluing Perrigo (PRGO) Right Now?
Perrigo Q2 Earnings Call Highlights
Perrigo Stock Rises 23% as Q2 Earnings & Sales Beat Estimates
Perrigo Company plc (PRGO) Q2 2026 Earnings Call Transcript
Perrigo (PRGO) Reports Q2 Earnings: What Key Metrics Have to Say
Perrigo (PRGO) Surpasses Q2 Earnings and Revenue Estimates
Perrigo Reports Second Quarter 2026 Financial Results From Continuing Operations
Perrigo Announces Quarterly Dividend
Perrigo to Present at the Canaccord 46th Annual Growth Conference
Perrigo to Release Second Quarter 2026 Financial Results on August 5, 2026
Perrigo Announces Appointment of Two New Independent Directors to Board
Mission Produce Posts Downbeat Q2 Earnings, Joins Ideaya Biosciences, Perrigo And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Perrigo CEO Ousted Over Personal Conduct
Perrigo Announces Leadership Transition
Perrigo: This 11% Yielder Should Cut The Dividend
Why Is Perrigo (PRGO) Down 9% Since Last Earnings Report?
Perrigo to Present at the Oppenheimer 26th Annual Consumer Growth & E-Commerce Conference
Perrigo Q1 Earnings Surpass Estimates, Sales Miss, Both Fall Y/Y